This is a preview of subscription content, log in via an institution to check access.
Reference
Cheng H, et al. Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes. Clinical Therapeutics : 1 Feb 2019. Available from: URL: http://doi.org/10.1016/j.clinthera.2019.01.003
Rights and permissions
About this article
Cite this article
Insulin degludec: small benefits in T2DM at high cost in China. PharmacoEcon Outcomes News 822, 17 (2019). https://doi.org/10.1007/s40274-019-5669-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5669-0